SR 12813, >=98%, solid

SR 12813, >=98%, solid

Application

SR-12813 was used as control in pregnane X receptor (PXR) binding assay performed in HepG2 liver carcinoma cells and PXR-activation assay mediated by dehydroepiandrosterone in human hepatocytes.

Biochem/physiol Actions

SR 12813 is a pregnane X receptor (PXR, NR 112) agonist; cholesterol lowering drug; HMGCoA reductase inhibitor.

SR-12813 is a 1,1-bisphosphonate ester that exhibits hypocholesterolemic activity. It decreases the biosynthesis of cholesterol by enhancing the degradation of HMG-CoA reductase.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

1, 5 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573905 SR 12813, >=98%, solid 100 YQLJDECYQDRSBI-UHFFFAOYSA-N 1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3 SIGMA-ALDRICH
£60.87 (exc VAT) per 1MG
-
+
3573906 SR 12813, >=98%, solid 100 YQLJDECYQDRSBI-UHFFFAOYSA-N 1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3 SIGMA-ALDRICH
£215.89 (exc VAT) per 5MG
-
+